Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects who have completed the 26 week Treatment Phase of Study 200952
Male or female
Able and willing to provide informed consent.
You may not be if
Subject meets one or more of the withdrawal stopping criteria at Visit 1 (Week 26)
Clareo Health | Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects
